Table 4. Allele frequency of rs10038177 with additional controls.
| Allele | Patient Subgroup | Frequency in Patient (no. of Chromosomes) | Frequency in Control (no. of Chromosomes) | p-value | OR (95% CI) | Relative risk (95% CI) |
|---|---|---|---|---|---|---|
| C |
POAG |
0.30 (197) |
0.27 (162) |
0.141 |
|
|
| |
HTG |
0.32 (88) |
|
0.002* |
1.216 (1.064–2.306) |
1.437 (1.139–1.799) |
| |
NON-HTG |
0.26 (109) |
|
0.886 |
|
|
| T |
POAG |
0.70 (449) |
0.73 (444) |
0.141 |
- |
- |
| |
HTG |
0.68 (144) |
|
0.002 |
- |
- |
| NON-HTG | 0.74(305) | 0.886 | - | - |
rs10038177 (c.710+30C>T) was found to be strongly associated with HTG patient group in the first phase of the study. To strengthen the observation, rs10038177 was genotyped in additional 184 controls and the SNP was still found to be strongly associated with HTG patient group. *Significant observation; P-value, OR and Relative Risk has been assessed with respect to C allele.